Want to join the conversation?
$PFE 2Q15 Q&A: Anderson of Bernstein asked an update on Enbrel. Geno replied that Enbrel continues to do well, 2% operational growth outside US on a large base. Overall, the company is not seeing or expecting a major shift in the Enbrel business related to the Remicade biosimilar, added Geno.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?